ClinicalTrials.gg
CompletedNCT03897543Updated Sep 29, 2026Results posted

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

A Phase 1/2 interventional study of ABX196 in Carcinoma, Hepatocellular, sponsored by Abivax S.A.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Abivax S.A. · Phase 1/2, Interventional, and Treatment

Updated Sep 29, 2026Now CompletedResults posted+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Enrollment
630th of 775
10 · median 36
Started
2020
with 34 others
Phase 1/2
112 of 926
29 open now
Registered
593rd of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 630th largest by enrollment of the 775 interventional ones that give a count, is one of 35 that started in 2020, is one of 112 in phase 1/2, and was the 593rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

Open-label, uncontrolled, Phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma

Read the detailed description

The goal of this clinical trial is to investigate if ABX196 in combination with nivolumab can benefit adult patients with hepatocellular carcinoma.

03

Conditions studied

  • Carcinoma, Hepatocellular

Keywords

  • HCC
  • Nivolumab
  • ABX196
04

Who can participate

The criteria were revised on the registry on Sep 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women, Age ≥18 years
  • Patients with performance status 0 or 1
  • Patients with confirmed diagnosis of HCC not amenable to curative surgery or local therapy
  • Patients who are intolerant to or who progressed on at least one line of Tyrosine Kinase Inhibitor (TKI) and/or (CPI) therapy
  • Patients eligible to be treated with nivolumab or under treatment with nivolumab
  • Patients with based on v1.1
  • Patients with class A liver score within 7 days of first study dose
  • Patients with no history of hepatic encephalopathy
  • Patients with no prior or current ascites as measured by physical examination and that requires active paracentesis for control (patients with ascites only on radiographic imaging are eligible)
  • Patients with infection must have received antiviral therapy for at least 12 weeks and HBV viral load must be documented to be \<100 IU/mL within 7 days of first study dose
  • Patients with no active co-infection with HBV and or HBV and HDV
  • Patients with no active drug or alcohol abuse
  • Patients with adequate organ function at screening

Exclusion criteria

Exclusion Criteria:

  • Patients with tyrosine kinase inhibitor treatment within 2 weeks of first study dose
  • Patients with esophageal or gastric variceal bleeding within the past 6 months
  • Patients with portal vein invasion at the main portal (Vp4) or the inferior vena cava or cardiac involvement of HCC based on imaging
  • Patients with previous solid organ or hematologic transplantation
  • Patients with active disease requiring systemic treatment in the past 2 years
  • Patients with diagnosis of immunodeficiency or receiving systemic therapy or other therapy within 7 days before first study dose
  • Patients with previous locoregional therapy or major surgery to the liver within 6 weeks before first study dose
  • Patients with minor surgery to liver or another site within 1 week before first study dose
  • Patients treated with an drug 2 weeks before first study dose
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Dose Escalation for ABX196

    Dose escalation: ABX196 at 0.1, 0.2, or 0.4 µg i.m. was administered after completion of nivolumab infusion on Day 1 of every other 28-day treatment cycle (i.e., every 8 weeks). Nivolumab 240 mg i.v. was administered on Days 1 and 15 of each 28-day cycle.

    Drug: ABX196

Interventions

  • DrugABX196

    ABX196 is a synthetic agonist of invariant Natural Killer T (iNKT) cells

    Also known as: Obefazimod

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs)

    Incidence and severity of adverse events evaluated according to CTC-AE

    Time frame: From first day of treatment (randomization visit) up to 64 weeks of treatment + up to 30 days of safety follow-up (total: up to 478 days)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Defined as the proportion of subjects with a best response of complete response or partial response according to RECIST V1.1

    Time frame: From first dose of treatment (randomization visit) up to 64 weeks treatment

  2. Progression Free Survival (PFS)

    Defined as time from first dose of ABX196 to disease progression or death

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks

  3. Time to Progression (TTP)

    Defined as time from first dose of study ABXX196 to disease progression or death

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks

  4. Change in Alpha Fetoprotein Serum

    Change in alpha fetoprotein serum concentrations

    Time frame: From first dose of treatment (randomization visit) up to 64 weeks treatment

07

Results

Posted Sep 29, 2026
Limitations and caveats
A standard 3+3 design was used for the Dose Escalation Phase of the study: 18 patients were to be accrued. 10 patients enrolled in the Dose Escalation Phase of the study: Cohort 1 - ABX196 0.1 μg: 4 Cohort 2 - ABX196 0.1 μg: 3 Cohort 3 - ABX196 0.1 μg: 3 Patients were heavily pretreated for HCC. The Expansion Phase of the study was not conducted.

Participant flow

Participant flow — Overall Study
MilestoneABX196 0.1 µg i.m.ABX196 0.2 µg i.m.ABX196 0.4 µg i.m.
Started433
Completed212
Not completed221

Outcome measures

PrimaryIncidence and Severity of Adverse Events (AEs)

Incidence and severity of adverse events evaluated according to CTC-AE

Time frame:
From first day of treatment (randomization visit) up to 64 weeks of treatment + up to 30 days of safety follow-up (total: up to 478 days)
Reported as:
Count of participants · Participants
Incidence and Severity of Adverse Events (AEs)
ParticipantsABX196 0.1 µg i.m.ABX196 0.2 µg i.m.ABX196 0.4 µg i.m.
Any TEAE, n (%)423
Any Serious TEAE, n (%)100
Any ABX196-related TEAE, n (%)220
Any nivolumab-related TEAE, n (%)320
Any serious ABX196-related TEAE, n (%)000
Any serious nivolumab-related TEAE, n (%)000
SecondaryObjective Response Rate (ORR)

Defined as the proportion of subjects with a best response of complete response or partial response according to RECIST V1.1

Time frame:
From first dose of treatment (randomization visit) up to 64 weeks treatment
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsABX196 0.1 µg i.m.ABX196 0.2 µg i.m.ABX196 0.4 µg i.m.
Objective Response Rate (ORR)100
Complete Response Rate (CR)000
Partial Response Rate (PR)100
SecondaryProgression Free Survival (PFS)

Defined as time from first dose of ABX196 to disease progression or death

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks
Reported as:
Median · Days
Progression Free Survival (PFS)
DaysABX196 0.1 µg i.m.ABX196 0.2 µg i.m.ABX196 0.4 µg i.m.
Progression Free Survival (PFS)340.5 (44 to NA)56 (53 to NA)56 (56 to NA)
SecondaryTime to Progression (TTP)

Defined as time from first dose of study ABXX196 to disease progression or death

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks
Reported as:
Median · Days
Time to Progression (TTP)
DaysABX196 0.1 µg i.m.ABX196 0.2 µg i.m.ABX196 0.4 µg i.m.
Time to Progression (TTP)340.5 (44 to NA)56 (53 to NA)56 (56 to NA)
SecondaryChange in Alpha Fetoprotein Serum

Change in alpha fetoprotein serum concentrations

Time frame:
From first dose of treatment (randomization visit) up to 64 weeks treatment
Reported as:
Count of participants · Participants
Change in Alpha Fetoprotein Serum
ParticipantsABX196 0.1 µg i.m.ABX196 0.2 µg i.m.ABX196 0.4 µg i.m.
Cycle 1 Day 1 AFP Responders, n (%)0—0
Cycle 1 Day 15 AFP Responders, n (%)0——
Cycle 2 Day 1 AFP Responders, n (%)0—0
Cycle 3 Day 1 AFP Responders, n (%)1—0
Cycle 4 Day 1 AFP Responders, n (%)1—0
Cycle 5 Day 1 AFP Responders, n (%)1—0
Cycle 6 Day 1 AFP Responders, n (%)1—0
Cycle 7 Day 1 AFP Responders, n (%)1—0
Cycle 8 Day 1 AFP Responders, n (%)1——
Cycle 9 Day 1 AFP Responders, n (%)1——
Cycle 10 Day 1 AFP Responders, n (%)1——
Cycle 11 Day 1 AFP Responders, n (%)1——
Cycle 12 Day 1 AFP Responders, n (%)1——
Cycle 13 Day 1 AFP Responders, n (%)1——
Cycle 14 Day 1 AFP Responders, n (%)1——
Cycle 15 Day 1 AFP Responders, n (%)1——
Cycle 16 Day 1 AFP Responders, n (%)0——
Termination AFP Responders, n (%)1—0

Adverse events

Collected over From first day of treatment (randomization visit) up to 64 weeks of treatment + up to 30 days of safety follow-up (total: up to 478 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABX196 0.1 µg0/4 (0%)1/4 (25%)4/4 (100%)
ABX196 0.2 µg0/3 (0%)0/3 (0%)2/3 (66.7%)
ABX196 0.4 µg0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventABX196 0.1 µgABX196 0.2 µgABX196 0.4 µg
CellulitisInfections and infestations1/4——
Most frequent other events
Showing 10 of 53
Most frequent other events
EventABX196 0.1 µgABX196 0.2 µgABX196 0.4 µg
FatigueGeneral disorders2/42/30/3
Platelet count decreaseInvestigations2/42/30/3
DiarrhoeaGastrointestinal disorders2/40/31/3
Abdominal pain lowerGastrointestinal disorders2/40/30/3
Back painMusculoskeletal and connective tissue disorders2/40/30/3
HypertensionVascular disorders2/40/30/3
CoughRespiratory, thoracic and mediastinal disorders2/40/30/3
Abdominal painGastrointestinal disorders1/41/30/3
VomitingGastrointestinal disorders0/41/30/3
Injection site painGeneral disorders0/41/30/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ABX196 0.1 µg i.mABX196 0.2 µg i.mABX196 0.4 µg i.mTotal
<=18 years0000
Between 18 and 65 years1214
>=65 years3126
Age, Continuous
Age, Continuous(Years)ABX196 0.1 µg i.mABX196 0.2 µg i.mABX196 0.4 µg i.mTotal
Mean65.8 (49 to 76)60.3 (53 to 67)64 (60 to 67)63.6 (49 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)ABX196 0.1 µg i.mABX196 0.2 µg i.mABX196 0.4 µg i.mTotal
Female0112
Male4228
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ABX196 0.1 µg i.mABX196 0.2 µg i.mABX196 0.4 µg i.mTotal
Race — Asian1113
Race — Black or African American0101
Race — White3126
Region of Enrollment
Region of Enrollment(Participants)ABX196 0.1 µg i.mABX196 0.2 µg i.mABX196 0.4 µg i.mTotal
United States43310
Hepatocellular Carcinoma
Hepatocellular Carcinoma(Participants)ABX196 0.1 µg i.mABX196 0.2 µg i.mABX196 0.4 µg i.mTotal
Count of participants43310
08

Study locations

2 sites
  • Scripps Clinic Torrey Pines
    La Jolla, California 92037, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Apr 2022, 25 months.

Results were first posted in Sep 2026, 4 years 5 months after primary completion.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 25 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Aug 2019 → Feb 2020, primary completion Jun 2021 → Apr 2022 and completion Jun 2023 → Apr 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Apr 1, 2019
StartActual
Feb 18, 2020was Aug 2019
Primary completionActual
Apr 14, 2022was Jun 2021
CompletionActual
Apr 14, 2022was Jun 2023
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 29, 2026
Results
Results posted
posted Sep 29, 2026
Start date
Aug 30, 2019→Feb 18, 2020
Sep 29, 2026
Primary completion
Jun 30, 2021→Apr 14, 2022 (actual)
Sep 29, 2026
Study completion
Jun 30, 2023→Apr 14, 2022 (actual)
Sep 29, 2026
Enrollment
48 (estimated)→10 (actual)
Sep 29, 2026
Eligibility
1 inclusion criterion edited, 2 added, 2 removed; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • RemovedPatients with documented objective radiographic progression during or after local therapy or after treatment with sorafenib or lenvatinib or intolerance to or refusal to receive either agent
  • RemovedPatients with at least one prior systemic therapy for HCC
  • AddedPatients who are intolerant to or who progressed on at least one line of Tyrosine Kinase Inhibitor (TKI) and/or Checkpoint inhibitor (CPI) therapy
  • EditedPatients eligible to be treated with nivolumab or under treatment with nivolumab
  • AddedPatients with adequate organ function at screening
Exclusion criteria
  • AddedPatients treated with an investigational drug 2 weeks before first study dose
Sep 29, 2026
Interventions
Arm changed ABX196→Dose Escalation for ABX196
Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedIncidence and Severity of adverse eventsAdverse Events (AEs)Time frame: Through study completion, an average of 1 year → From first day of treatment (randomization visit) up to 64 weeks of treatment + up to 30 days of safety follow-up (total: up to 478 days)
Sep 29, 2026
Documents
Secondary outcomes
3 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedProgression- Free Survival (PFS)Time frame: From date of randomization until the date of first documented progression, assessed up to 24 months → From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks
  • EditedChange in Alpha Fetoprotein Serum concentrationsTime frame: Every 2 weeks, assessed up to 12 months → From first dose of treatment (randomization visit) up to 64 weeks treatment
  • ChangedBefore Duration of Response (DOR)Now Time to Progression (TTP)Time frame: From date of randomization until the date of first documented progression, assessed up to 12 months → From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks
  • Time frameObjective Response Rate (ORR)From date of randomization until the date of first documented progression, assessed up to 12 months → From first dose of treatment (randomization visit) up to 64 weeks treatment
  • DescriptionObjective Response Rate (ORR): how it is measured was reworded
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Completed
    Results posted
    Start date Aug 30, 2019→Feb 18, 2020
    Primary completion Jun 30, 2021→Apr 14, 2022 (now actual)
    Study completion Jun 30, 2023→Apr 14, 2022 (now actual)
    Enrollment 48 (estimated)→10 (actual)
    Eligibility 1 inclusion criterion edited, 2 added, 2 removed; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients with documented objective radiographic progression during or after local therapy or after treatment with sorafenib or lenvatinib or intolerance to or refusal to receive either agent
    • RemovedPatients with at least one prior systemic therapy for HCC
    • AddedPatients who are intolerant to or who progressed on at least one line of Tyrosine Kinase Inhibitor (TKI) and/or Checkpoint inhibitor (CPI) therapy
    • EditedPatients eligible to be treated with nivolumab or under treatment with nivolumab
    • AddedPatients with adequate organ function at screening
    Exclusion criteria
    • AddedPatients treated with an investigational drug 2 weeks before first study dose
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedIncidence and Severity of adverse eventsAdverse Events (AEs)Time frame: Through study completion, an average of 1 year → From first day of treatment (randomization visit) up to 64 weeks of treatment + up to 30 days of safety follow-up (total: up to 478 days)
    Secondary outcomes 3 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedProgression- Free Survival (PFS)Time frame: From date of randomization until the date of first documented progression, assessed up to 24 months → From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks
    • EditedChange in Alpha Fetoprotein Serum concentrationsTime frame: Every 2 weeks, assessed up to 12 months → From first dose of treatment (randomization visit) up to 64 weeks treatment
    • ChangedBefore Duration of Response (DOR)Now Time to Progression (TTP)Time frame: From date of randomization until the date of first documented progression, assessed up to 12 months → From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks
    • Time frameObjective Response Rate (ORR)From date of randomization until the date of first documented progression, assessed up to 12 months → From first dose of treatment (randomization visit) up to 64 weeks treatment
    • DescriptionObjective Response Rate (ORR): how it is measured was reworded
    Interventions Arm changed ABX196→Dose Escalation for ABX196
    + 8 other changes: verification date, registry dates, responsible party, description, design details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03897543
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Apr 1, 2019
Start date
Feb 18, 2020
Primary completion
Apr 14, 2022
Completion
Apr 14, 2022
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Darren SIGAL, MD
principal investigator · Scripps Clinic/Scripps MD Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion